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Abstract
Background: Microfracture is a first-line treatment option for cartilage repair. In microfracture, subchondral
mesenchymal cortico-spongious progenitor cells (CSP) enter the defect and form cartilage repair tissue. The aim of
our study was to investigate the effects of joint disease conditions on the in vitro chondrogenesis of human CSP.
Methods: CSP were harvested from the subchondral bone marrow. CSP characterization was performed by analysis
of cell surface antigen pattern and by assessing the chondrogenic, osteogenic and adipogenic differentiation
potential, histologically. To assess the effect of synovial fluid (SF) on chondrogenesis of CSP, micro-masses were
stimulated with SF from healthy (ND), osteoarthritis (OA) and rheumatoid arthritis donors (RA) without transforming
growth factor beta 3.
Results: CSP showed the typical cell surface antigen pattern known from mesenchymal stem cells and were
capable of osteogenic, adipogenic and chondrogenic differentiation. In micro-masses stimulated with SF,
histological staining as well as gene expression analysis of typical chondrogenic marker genes showed that SF
from ND and OA induced the chondrogenic marker genes aggrecan, types II and IX collagen, cartilage oligomeric
matrix protein (COMP) and link protein, compared to controls not treated with SF. In contrast, the supplementation
with SF from RA donors decreased the expression of aggrecan, type II collagen, COMP and link protein, compared
to CSP treated with SF from ND or OA.
Conclusion: These results suggest that in RA, SF may impair cartilage repair by subchondral mesenchymal
progenitor cells in microfracture, while in OA, SF may has no negative, but a delaying effect on the cartilage matrix
formation.
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Background
Different cartilage regeneration strategies and techniques
are used in clinical routine today. Especially, bone mar-
row stimulating techniques like pride drilling [1] and
microfacture technique [2] are frequently used. Micro-
fracture involved the debridement of damaged tissue
down to the subchondral bone to induce bleeding, thus
allowing mesenchymal progenitor cells derived from the
subchondral bone, cortico-spongious progenitor cells
(CSP) to enter the defect. These CSP are characterised
by high proliferation capacity and the ability to differ-
entiate into bone, cartilage and fat. Also CSP show the
typical cell surface markers known from mesenchymal
s t e ma n dp r o g e n i t o rc e l l s ,s u c ha sC D7 3 ,C D9 0 ,C D
105 and CD 166 [3-6]. The migration and recruitment
of such CSP is mediated by cytokines and growth fac-
tors, also present in varying amounts in human synovial
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any medium, provided the original work is properly cited.fluid (SF) [7-9]. These progenitor cells that reside in the
subchondral bone form a non-hyaline cartilage repair
tissue [10]. Additionally, there is evidence that the struc-
ture of the repair tissue formation may depend on the
composition of SF. For example, SF from donors with
trauma or osteoarthritis (OA) stimulated bovine chon-
drocytes to a higher extent of proteoglycan synthesis
than the SF of rheumatoid arthritis (RA) donors [11]. In
addition it has been shown that SF from acutely injured
knees stimulated chondrogenesis, whereas SF from
chronically injured knees inhibited chondrogenic differ-
entiation [12]. It is also known that in both arthritic dis-
eases (RA and OA) the SF contains inflammatory
mediators such as cytokines, chemokines, matrix metal-
loproteinases (MMP), tumor necrosis factor-alpha
(TNF-a), interleukins and growth factors which play a
major role during the etiopathology of the disease. Also
the protease and proteinase inhibitors TIMP1, TIMP2
and a2-macroglobulin (a2M) are involved in this pro-
cess. But in RA patients the inflammatory mediators
were increased compared to OA patients [13-19]. The
protease and proteinase inhibitors were decreased in RA
patients compared to OA patients [17,19]. However, in
both diseases there is a clear correlation of an inflamma-
tory mediator/proteinase inhibitor imbalance compared
to healthy individuals, which have a balanced inflamma-
tion mediator/proteinase inhibitor ratio. It is also known
that mesenchymal progenitor cells from patients with
RA and OA have the similar chondrogenic potential as
mesenchymal progenitor cells from healthy donors [20].
In summary, in both arthritic diseases (RA and OA)
inflammatory mediators such as cytokines, chemokines,
MMPs and growth factors play a major role during the
onset and progression of the disease. In both diseases
there is a clear agreement of an inflammatory mediator/
proteinase inhibitor imbalance compared to healthy
individual, which have an inflammatory mediator/protei-
nase inhibitor balance [17,19]. It is also known that
mesenchymal progenitor cells from patients with RA
and OA have the similar chondrogenic potential as
mesenchymal progenitor cells from healthy donors (ND)
[20]. Further, experiments showed that an OA environ-
ment does not impair cell migration compared to a
healthy environment. In contrast, RA environment
reduced the cell migration capacity of progenitor cells
compared to OA and ND environment [8] and we have
shown that inflammatory synovial fluid derived from
donors with rheumatoid arthritis inhibits the chondro-
genic differentiation sequence induced by the growth
and differentiation factor TGFB3, transforming growth
factor beta 3 [4]. To resemble more closely the clinical
situation, the aim of the current study was to evaluate
the effect of human synovial fluid from normal, rheuma-
toid arthritis and osteoarthritis donors on the
chondrogenic differentiation of human subchondral cor-
tico-spongious progenitor cells, without any external
chondrogenic stimulus by recombinant growth factor
TGFB3.
Methods
Isolation and cultivation of cortico-spongious progenitor
cells (CSP)
Human CSP were isolated from subchondral cortico-
spongious bone chips (n = 4 donors; two females, two
males, age 29-67 years) from the lateral tibia head dur-
ing high tibial closed wedge osteotomy as described pre-
viously [3]. The ethics committee of the Charité-
Universitätsmedizin Berlin approved the study. In brief,
spongious bone chips were cut into small fragments and
digested for 4 h at 37°C using 256 U/mL collagenase XI
(Sigma, St. Louis, MO, USA). The fragments were
placed in Primaria™ culture flasks (Becton and Dickin-
son, Franklinlakes, NJ, USA) and cultured in DME-med-
ium (Biochrom, Berlin, Germany) containing 10%
human serum (German Red Cross, Berlin, Germany),
100 U/mL penicillin, 100 μg/mL streptomycin, 2 mM L-
glutamine (all Biochrom), and 2 ng/ml fibroblast growth
factor-2 (Tebu-bio, Boechout, Belgium). Cells that
reached 80-90% confluence were subcultivated using
t r y p s i ni nP B S( 0 . 0 5 %v / v ,B i o c h r o m )a n dr e - p l a t e da ta
density of 6,000 cells/cm
2. Medium was exchanged
every 2-3 days.
Flow cytometric analysis
CSP (250,000 cells, passage 3) were washed in PBS/0.5%
BSA and incubated with monoclonal mouse anti-human
labeled antibodies CD34-Phycoerythrin (PE), CD73-PE,
CD166-PE, CD45-Fluorescein-iso-thio-cyanate (FITC),
CD90-FITC and CD105-FITC (all Becton and Dickin-
son) for 15 minutes. Staining of cell surface antigens
was analyzed using FACS Calibur (Becton and Dickin-
son). Apoptotic cells were excluded from analysis using
propidium iodide (PI). CD34 stained cells served as iso-
typic negative control.
Collection of synovial fluid (SF)
Rheumatoid arthritis (RA) SF was obtained by joint
puncture (n = 7; six female, one male; mean age 42
years; mean DAS 28 5.8; mean ESR (1 h) 58; mean CrP
5.8 mg/dL) from patients with an acute inflammatory
phase diagnosed according to the revised American Col-
lege of Rheumatology criteria for the Classification of
RA [21]. Four donors with RA received disease modify-
ing anti-rheumatic drugs (DMARD), three donors
received steroidal anti-inflammatory drugs (SAID), three
donors received non-steroidal anti-inflammatory drugs
(NSAID), and two donors were treated with anti-tumor
necrosis factor-a (anti-TNF therapy). None of the
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(OA) SF was obtained by joint puncture (n = 7; six
females, one male; mean age 64 years; mean ESR (1 h)
12; mean CrP 0.7 mg/dL) from patients diagnosed
according to the American College of Rheumatology cri-
teria for the classification and reporting of OA [22].
Four of the donors with OA received NSAID and three
donors had no medication at the time of joint puncture.
None of the OA donors received intra-articular therapy.
Normal (ND) SF was obtained post mortem within 24
hours from organ donors (n = 7; three females, four
males; mean age 61 years). By visual inspection of the
joint and in particular the articular cartilage, normal
donors with joint diseases were excluded. All procedures
were performed in consent with the ethics committee of
the Charité-Universitätsmedizin Berlin.
Assessment of mesenchymal lineage differentiation
potential of CSP
For osteogenic and adipogenic differentiation, CSP (n =
4 donors) were plated with a density of 5,000 cells in 6-
well culture plate (Becton and Dickinson). For osteo-
genic differentiation, confluent monolayer cultures were
stimulated with low-glucose DME-medium containing
10% human serum and osteogenic supplements (0.1 μM
dexamethasone, 50 μM L-ascorbic acid-2-phosphate, 10
mM b-glycerophosphate; (all Sigma) [23]. Cells were
cultured for 18 days and medium was changed every
other day. For adipogenic differentiation, cells were sti-
mulated 3 days post confluence with high-glucose
DME-medium containing 10% human serum and adipo-
genic supplements (1 μM dexamethasone, 200 μM indo-
methacin, 50 μM 3-isobutyl-1-methylxanthin; (all Sigma)
[24]. Cells were cultured for 20 days. Controls were
maintained without adipogenic or osteogenic supple-
ments. Chondrogenic differentiation of CSP (passage 3)
was performed under serum-free conditions in high-
density pellet cultures (n = 4 donors, 250,000 cells/pel-
let) as described previously [25]. Chondrogenesis was
induced by adding 10 ng/ml transforming growth factor
beta 3 (TGFB3, R&D Systems, Minneapolis, MN, USA).
The medium was exchanged every 2-3 days and cells
were maintained for up to 28 days. Controls were main-
tained without TGFB3 supplements.
Chondrogenic differentiation in the presence of human
synovial fluid
To evaluate the influence of RA, OA and ND-SF on
chondrogenic differentiation of CSP, pellets were treated
with DME-medium (ITS + 1 (Insulin-Transferrin-Sele-
nium), 0.1 μM dexamethasone, 1 mM sodium pyrovate,
0.17 mM ascorbic acid-2-phosphate, 0.35 mM proline
(all Sigma) supplemented with 5% of the respective SF
(pooled from seven donors, equal amounts) without
TGFB3. Pellets cultured in DME-medium in the absence
of SF served as controls. The medium was exchanged
every 2 -3 days and cells were maintained for up to 28
days.
Histochemical and immune-histochemical staining
From all donors (n = 3 cell pellets, n = 3 sections per
cell pellet for n = 4 donor), cryosections (6 μm) were
made and subsequently stained using a primary rabbit
anti-human type II collagen antibody (Acris, Hiddenhau-
sen, Germany). Therefore, sections were incubated for
40 minutes with antibody, colorimetrically detected by
3-amino-9-ethylcarbazole (EnVision™, Dako, Glostrup,
Denmark) and counterstained with hematoxylin (Merk,
Darmstadt, Germany). In addition, proteoglycans of CSP
treated with SF (n = 3 cell pellets, n = 3 sections per
cell pellet for each individual experiment) were visua-
lized by staining Alcian Blue 8GS (Roth, Karlsruhe, Ger-
many) at pH 2.5, followed by counterstaining with
nuclear fast red (Sigma). Osteogenic cells were detected
by staining of mineralized matrix components according
to von Kossa. Intracellular lipid vacuoles in adipogenic
cultures were visualized using Oil Red O staining
(Sigma).
Polymerase chain reaction (PCR)
As indicated, total RNA from 20 pellets per experiment
was isolated as described previously [26]. Subsequently,
total RNA (3 μg) was reversely transcribed with the
iScript cDNA Synthesis Kit according to the manufac-
turer’s instructions (BioRad, München, Germany). The
relative expression level of housekeeping gene glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) was used
to normalize samples. Real-time RT PCR using i-Cycler
PCR System (BioRad) was performed with 1 μL of each
cDNA sample in triplicate using the SYBR green PCR
Core Kit (Applied Biosystems, Foster City, CA, USA).
Relative quantification of marker gene (Table 1) expres-
sion was performed and is given as percentage of the
GAPDH product or as fold change according to the
ΔCT-method [27]. Differential expression was consid-
ered at fold change of FC > 2 or FC < 2.
Results
Morphology and cell surface antigen pattern of human
CSP
Cultured primary CSP presented a spindle-shaped, non-
granular fibroblast-like morphology and formed colo-
nies. Subcultured cells grew in monolayer, maintained a
stable fibroblast-like morphology with no signs of granu-
lation. Expanded CSP showed typical cell surface anti-
gens known from mesenchymal stem and progenitor
cells. All CSP were homogenously positive (92%-100%)
for CD75, CD90, CD105 and CD166. Cells were
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tive cells) and for the leukocyte common antigen CD45
(0.1% positive cells) (Figure 1).
Differentiation potential of CSP
The potential of CSP to undergo osteogenic, adipogenic
and chondrogenic differentiation was documented by
visualization of matrix mineralization by von Kossa
staining, by visualization of lipid vesicles by Oil Red O
staining and by visualization of type II collagen by
immune-histochemistry (Figure 2). At day 18, von Kossa
staining showed in CSP-cultures stimulated with osteo-
genic supplements zones of high calcium content (A). In
Table 1 Oligonucleotides used for gene expression analysis
Gene name Gene
symbol
Oligonuclotides (5’®3’) (Up/Down) Product size (Base
Pairs)
Glyceraldehyd-3-Phosphate
dehydrogenase
GAPDH GGC GAT GCT GGC GCT GAG TAC/TGG TCC ACA CCC ATG ACG A 149
Aggrecan AGC1 CCA GTG CAC AGA GGG GTT TG/TCC GAG GGT GCC GTG AG 146
Cartilage oligomeric matrix protein COMP GGG TGG CCG CCT GGG GGT CTT/CTT GCC GCA GCT GAT GGG TCT C 116
Link-protein LINK GCG TCC GCT ACC CCA TCT CTA/GCG CTC TAA GGG CAC ATT CAG TT 145
Type IIa1 collagen COL2A1 CCG GGC AGA GGG CAA TAG CAG GTT/CAA TGA TGG GGA GGC GTG AG 128
Type IXa1 collagen COL9A1 AAT CAG GCT CTG AAG CTC ATA AAA/CCT GCC ACA CCC CCG CTC CTT
CAT
100
Matrix metalloproteinase 1 MMP1 TAC ATG CGC ACA AAT CCC TTC TAC C/GAA AAA CCG GAC TTC ATC
TCT GTC G
126
Matrix metalloproteinase 2 MMP2 TCC CTG CCC CTC CCT TCA AC/CCT TTC CAG CAG ACA CCA TCA CC 196
Matrix metalloproteinase 13 MMP13 CAA AAA CGC CAG ACA AAT GTG ACC/GAT GCA GGC GCC AGA AGA
ATC T
105
Tissue inhibitor of
metalloproteinases 1
TIMP1 GGC TTC TGG CAT CCT GTT GTT G/ACG CTG GTA TAA GGT GGT CTG GTT
G
160
Tissue inhibitor of
metalloproteinases 2
TIMP2 CTA GGG CAG ACT GGG AGG GGG AGG GTA TC/TGG AGG GGT CTG GTG
GAG TTG TAT
143
Figure 1 FACS analysis of cultured CSP.H i s t o g r a m so b t a i n e d
from FACS analysis of culture expanded CSP. Cells were positive for
the surface antigens CD 73, CD 90, CD 105 and CD 166 and
negative for CD 34 and CD 45. The illustration is representative for
all donors in FACS analysis.
Figure 2 Assessment of mesenchymal lineage differentiation
potential of CSP. Von Kossa staining for documentation of matrix
mineralization showed (A) that, at day 18, mineralization was
evident in osteogenic induced cultures. (B) In non-induced cultures
no matrix mineralization was detected. Oil Red O staining for
documentation of adipogenic differentiation showed (C) that, at
day 20, lipid vacuoles were evident in adipogenic-induced cultures.
(D) In non-induced cultures no lipid vacuoles were detected. Type II
collagen staining showed (E) that, at day 28, type II collagen was
evident in chondrogenic induced CSP. (F) In non-induced cells no
type II collagen was detected. These illustrations are representative
for all donors.
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detected (B). At day 20, Oil Red O staining showed that
lipid-filled vesicles were present in CSP stimulated with
adipogenic supplements (C). In non-stimulated controls
no lipid vesicles were detected (D). Immune-histochem-
ical staining of CSP pellets stimulated with TGFB3
showed that CSP developed a dense tissue, rich in viable
cells and deposition of cartilage-specific type II collagen,
at day 28 (E). In absence of TGFB3, pellets showed no
type II collagen deposition (F).
Chondrogenic differentiation with synovial fluid
Histochemical staining of CSP pellets showed that con-
trol pellets and pellets cultured in presence of ND or
OA-SF (without TGFB3) evolved a dense tissue, rich in
viable cells and marginal proteoglycan in the centre area
(Figure 3). However, pellets cultured in presence of RA-
SF evolved a more compact tissue compared to pellets
cultured in the presence of ND or OA-SF. No proteo-
glycan was detectable in pellets treated with RA-SF.
Immune-histological staining of type II collagen showed
that control pellets and pellets cultured in presence of
SF (ND, OA or RA) was void of type II collagen (Figure
4) at day 28. There was also no type II collagen detect-
able at day 1, 7, 14, 21 (data not shown).
Gene expression analysis of human subchondral CSP
undergoing chondrogenic differentiation
Gene expression analysis of CSP pellets stimulated
with synovial fluid without TGFB3 showed differences
in the expression of type II collagen, proteoglycans,
and link-protein, which was detected at day 14 of
chondrogenic differentiation (Figure 5). CSP stimulated
with ND or OA-SF showed induction of the gene
expression of the chondrogenic marker gene type II
collagen (from 0.1% to 0.4%-4%) compared to the con-
trol. CSP stimulated with ND or OA synovial fluid
showed elevated expression of the chondrogenic mar-
ker genes aggrecan (from 0.15% of the expression level
of GAPDH in controls to 1-1.5% in CSP treated with
ND-SF or OA-SF), the cartilage oligomeric matrix pro-
tein (COMP) (from 0.3% to 1.4-1.6%) and the link-pro-
tein (from 0.15% to 0.3-0.9%). RA-SF similar induced
the expression of aggrecan, COMP and link-protein of
CSP compared to CSP treated without TGFB3 and
synovial fluid (control). Additional OA-SF induced the
expression of type IX collagen (from 0.2% to 3.4%).
Whereas, the gene expression of type IX collagen in
ND or RA-SF stimulated cells remained on the same
level as the control.
Compared to control, CSP stimulated with ND-SF or
RA-SF showed an increase in the expression of genes
related to matrix remodeling like MMP1 (from 0.05% to
0.1-0.2%), whereas CSP induced with OA-SF presented
a similar expression of the MMP1 gene compared to the
control. Furthermore CSP stimulated with SF’sp r e -
sented a similar expression of the MMP2 and TIMP1
genes compared to the control. Compared to control,
the expression of MMP13 (from 7.2% to 0.8-3%) and
metalloprotease inhibitor TIMP2 (from 293% to 96-
120%) was repressed in CSP co-stimulated with synovial
fluids only.
Since the presence of ND-SF represents the physiolo-
gical condition in healthy joints, the gene expression
levels of the respective markers in the diseased condi-
tion were calculated in relation to the ‘normal situation’
(Figure 6). At day 7, compared to CSP treated with ND-
SF, SF from OA induced COMP (FC = 2.0) and MMP1
(FC = 4.3), whereas the marker gene type II collagen
(FC = -7.1) was repressed. SF from RA induced MMP1
(FC = 6.4), and the marker gene type II collagen (FC =
-5.7 was repressed. At day 14 compared to CSP treated
with ND-SF, SF from OA induced the marker genes
type II collagen (FC = 6.9), aggrecan (FC = 2.0), link-
protein (FC = 3.9) and type IX collagen (FC = 7.3). SF
from RA showed no significant changes in chondrogenic
marker gene levels compared to ND-SF at day 14.
N e v e r t h e l e s s ,at e n d e n c yo fi n c r e a s eo ft y p eI Ic o l l a g e n ,
aggrecan, COMP and link-protein can be observed at
day 14 compared to ND-SF.
Figure 3 Alcian blue staining of CSP pellet cultures. Alcian blue staining of CSP pellet cultures cultured in the presence of synovial fluid from
ND, OA or RA donors, at day 28.
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This study was performed to clarify some preliminary
effects on the in vitro chondrogenic differentiation
potential of cortico-spongious progenitor cells (CSP)
affected by synovial fluid (SF) obtained from healthy
donors (ND) and patients with OA or RA. For this pur-
pose, CSP were analyzed histochemically for aggrecan
and type II collagen. Also gene expression analyses of
cartilage specific marker genes were performed. Because
there is a lag of basic understanding in the principles in
cell biology and especially in the interaction of the cells
with the surrounding envir o n m e n tt h a tc o n t r o l sa n d
directs function. Few studies indicate that synovial fluid
(SF) compounds affect the in vivo environment of carti-
lage in osteoarthritis (OA) and rheumatoid arthritis
(RA) patients [16,28]. It could be demonstrated that
RA-SF impaired the chondrogenic differentiation of
human subchondral progenitor cells [4]. Therefore, it
remains unclear, if engineered tissue or manufactured
material for cartilage repair can be placed in patients
with OA or RA. It is known that under normal condi-
tions the cartilage matrix is subjected to a dynamic
remodeling process in which low levels of degradative
and synthesizes enzyme activities are balanced, such
that natural turnover of cartilage is maintained [29]. In
OA and RA cartilage, however, matrix degrading
enzymes are over expressed, shifting this balance to
increased degradation resulting in loss of collagen and
proteoglycans from the matrix [17,30].
To verify the homogeneity of cell population, the
functional characteristics of the isolated CSP from each
donor were analyzed. The analysis contains the investi-
gation of certain surface antigens and the multi-differen-
tiation potential. The results showed that all human CSP
isolated from tibia grown exponential in the presence of
human serum and present the typical mesenchymal pro-
genitor cell related cell surface antigen pattern. Also,
CSP have the ability to undergo osteogenic, adipogenic
and chondrogenic differentiation. These findings con-
firm with the international society for cellular therapy
position statement, which define the minimal criteria for
mesenchymal progenitor cells [31] and some published
articles which deal with the characterization of
mesenchymal progenitor cells derived from subchondral
bone [3,5,6].
It is believed that cytokines and growth factors play an
important role in the pathophysiology of OA and RA
[13,28]. They are closely associated with functional
alterations in synovium, cartilage and subchondral bone
and are produced both spontaneously and following sti-
mulation by joint tissue cells. Moreover, several of these
agents (e.g. a2-macroglobulin (a2 M), metalloprotei-
nases (MMP) and proteinase inhibitors TIMP) have
been identified in human synovial fluid [17,32]. The
MMP are the major proteolytic enzymes that facilitate
tissue remodeling in both physiological and pathological
situations. The MMP do indeed have the combined abil-
ity to degrade the major components of the cartilage
extracellular matrix such like type II collagen and aggre-
can (Figure 7) [29,33]. However, it should be taken into
account that the alterations found in OA and RA com-
pared to the healthy situation may not be represented
by the synovial fluids used in the current study. A clear
limitation might be that the SF from normal donors was
obtained post-mortem and therefore may show non-
physiological changes in its composition compared to a
healthy or traumatic SF. In addition, disease-related
medical treatment of the donors may lead to alterations
in the SF composition. Therefore, further studies have
to elucidate whether SAID or NSAID have an impact
on the composition of SF and in turn of the chondro-
genic differentiation of progenitors in the presence of
the respective SF.
The gene expression analysis of chondrogenic marker
genes in CSP treated with synovial fluid showed that the
cartilage marker genes COMP, link-protein, aggrecan
and type II collagen are slightly increased after 14 days
in high-density cultures of CSP under serum-free condi-
tions. These findings underline the fact that synovial
fluid contains factors such like hyaluronic acid which
promotes and enhances the development of cartilage by
mesenchymal stem and progenitor cells [7]. Synovial
Figure 4 Type II collagen staining of CSP pellet cultures. Type II collagen staining of CSP pellet cultures at day 28 cultured without TGFB3
but in presence of synovial fluid. The illustration is representative for all other samples, which were taken at day 1, 7, 14 and 21.
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Page 6 of 10Figure 5 Gene expression analysis of CSP pellet cultures. Semi-quantitative real-time gene expression analysis of human CSP pellets treated
with synovial fluid from ND, OA and RA donors. Chondrogenic differentiation of CSP was analyzed by gene expression analysis (n = 3) of the
typical chondrocytic marker genes aggrecan, cartilage oligomeric matrix protein (COMP), link-protein type II and type IX collagen. Matrix
remodelling was assessed by gene expression analysis of the matrix metalloproteinases (MMP)-1, -2 and -13 as well as their inhibitors (TIMP)-1
and -2. The expression level of marker genes was calculated as percentage of the expression level of the housekeeping gene GAPDH. The mean
of each triplicate is plotted and the error bars represent SD.
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Page 7 of 10Figure 6 Effect of rheumatoid arthritis and osteoarthritis synovial fluid on the chondrogenic differentiation of CSP. Differential
expression of maker genes in CSP treated with synovial fluid from ND, OA and RA donors. To assess the effect of rheumatoid arthritis and
osteoarthritis on the “normal” chondrogenic differentiation of subchondral progenitors, the expression profile of the typical chondrogenic marker
genes aggrecan, cartilage oligomeric matrix protein (COMP), link-protein type II and type IX collagen was evaluated. Matrix remodelling was
assessed by gene expression analysis of the matrix metalloproteinases (MMP)-1, -2 and -13 as well as their inhibitors (TIMP)-1 and -2 and is given
as fold change compared to the expression level in CSP treated with normal synovial fluid. The mean of each triplicate well is plotted and the
error bars represent SD.
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blast growth factors (FGF) and bone morphogenetic
proteins (BMP), which are able to induce the chondro-
genic differentiation [28,32]. However, the stimulation
with synovial fluid was not sufficient to detect some
aggrecan or type II collagen on protein level, but it was
detectable on mRNA level. To clarify the question of
dependency of the MMP/TIMP production, the gene
expression data of CSP cultured with synovial fluid (ND,
O Ao rR A )s h o w e dt h a tt h em R N Al e v e li sd e c r e a s e d
for MMP1 and MMP3 during cultivation of CSP treated
with OA-SF and RA-SF compared to CSP treated with
ND-SF. However, the mRNA level of MMP2, TIMP1
and TIMP2 showed a similar expression during the cul-
tivation of CSP treated with ND-SF, OA-SF or RA-SF.
Therefore, the CSP are not responsible for the MMP/
TIMP imbalance in RA and OA synovial fluid. As a
consequence it can be assumed that only synovial cells
are involved in the MMP/TIMP ratio balance or imbal-
ance. This findings correlate with a published article,
which supposed that chondrocytes are not involved in
the development of the MMP/TIMP ratio in SF [34].
Moreover, this study showed that supplementation of
the chondrogenic culture medium (without TGFB3)
with synovial fluid from OA induced the marker genes
aggrecan, type II collagen, link-protein and type IX col-
lagen at day 14, compared to CSP treated with ND-SF.
S oi tm i g h tb ep o s s i b l et h a tt h es a m em e c h a n i s mw e r e
activated, which is responsible in OA cell cluster forma-
tion for the expression and synthesis of new compo-
nents of extracellular matrix [34,35]. This suggests that
wound healing, including collagen synthesis, occurs in
damaged OA cartilage. Additionally, the results demon-
strated that ND-SF also induces chondrogenesis on
RNA level of CSP. In contrast, the supplementation of
the chondrogenic culture medium with RA-SF reduced
chondrogenesis of CSP compared to ND-SF. Reflecting
results obtained in this study and the knowledge from
the literature, a RA environment reduces the cartilage
regeneration [4]. So it might be possible to use tissue
engineering strategies for cartilage repair in the early
stage of osteoarthritis. But the etiology of the pathogenic
cartilage defect needs to be eliminated before [36]. Also
the beginning of an inflammatory process should be
treated with anti-inflammatory therapeutics. Extremely
questionable is the use of cell based strategies for carti-
lage replacement in RA patients. In this study it was
demonstrated that RA-SF has an effect on the mRNA
level of chondrogenesis. To further clarify these facts an
in vivo OA and RA model is necessary.
Conclusions
In conclusion our study showed that rheumatoid arthri-
tis synovial fluid impairs the chondrogenic differentia-
tion of human subchondral progenitor cells, whereas
osteoarthritis fluid induced after 14 days the mRNA
level of aggrecan, type II collagen, link-protein and type
IX collagen compared to rheumatoid synovial fluid.
These results indicate that an inflammatory environ-
ment found in rheumatoid arthritis negatively affects the
chondrogenesis during cartilage repair, while an osteoar-
thritis environment may not impair, but delay the carti-
lage repair by subchondral progenitor cells.
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